Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Author:

Amano Masayuki1,Otsu Sachiko1,Uemura Yukari2,Ichikawa Yasuko3,Matsumoto Shota3,Higashi-Kuwata Nobuyo4,Matsushita Shuzo1,Shimada Shinya3,Mitsuya Hiroaki4

Affiliation:

1. Kumamoto University

2. National Center for Global Health and Medicine (NCGM)

3. Kumamoto General Hospital

4. NCGM Research Institute

Abstract

Abstract SARS-CoV-2-BA.4/5-adapted-bivalent-BNT162b2-vaccine (bvBNT), developed in response to the recent emergence of immune-evasive Omicron-variants, has been given to individuals who completed at least 2-doses of the monovalent-BNT162b2-vaccine (mvBNT). In the present cohort study, we evaluated neutralization-titers (NT50s) against Wuhan-strain (SCoV2Wuhan) and Omicron-sublineages including BA.2/BA.5/BQ.1.1/XBB/XBB.1.5, and vaccine-elicited S1-binding-IgG in sera from participants-vaccinated with 5th-bvBNT following 4th-mvBNT. The 5th-bvBNT-dose elicited good protective-activity against SCoV2Wuhan with geometric-mean (gMean)-NT50 of 1,966~2,091, higher than the peak-values post-4th-mvBNT, and favorable neutralization-activity against not only BA.5 but also BA.2, with ~3.2-/~2.2-fold greater gMean-NT50 compared to the peak-values post-4th-mvBNT-dose, in participants with or without risk-factors. However, neutralization-activity of sera post-5th-bvBNT-dose was low against BQ.1.1/XBB/XBB.1.5. Interestingly, participants receiving bvBNT following breakthrough (BT) infection during Omicron-wave had significantly enhanced neutralization-activity against SCoV2Wuhan/BA.2/BA.5 with ~4.6-/~6.3-/~8.1-fold greater gMean-NT50, respectively, compared to uninfected participants receiving bvBNT. Sera from BT-infected-participants receiving bvBNT had enhanced neutralization-activity against BQ.1.1/XBB/XBB.1.5 by ~3.8-fold compared to those from the same participants post-4th-mvBNT-dose, and had enhanced gMean-NT50 ~5.4-fold greater compared to those of uninfected-participants’ sera post-bvBNT. These results suggest that repeated stimulation brought about by exposure to BA.5’s-Spike elicit favorable cross-neutralization-activity against various SARS-CoV-2-variants, and that bvBNT vaccination be administered in particular to the individuals who experienced BT-infection.

Publisher

Research Square Platform LLC

Reference21 articles.

1. World Health Organization. COVID-19 Weekly Epidemiological Update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-february-2023 (accessed date: 14-Feb.2023).

2. A new coronavirus associated with human respiratory disease in China;Wu F;Nature,2020

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou P;Nature.,2020

4. Sustaining containment of COVID-19: global sharing for pandemic response;Mitsuya H;Glob Health Med.,2020

5. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities;Dal-Ré R;Lancet Infect Dis.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3